Discover how abnormal sleep duration and insomnia are linked to an increased risk for cardiometabolic disease and mortality in adults.

Adults hospitalized with epilepsy who live in rural areas face a higher risk for mortality and status epilepticus than urban patients.

Kalshi and AppliedXL launch a pilot prediction market for late-stage clinical trial outcomes and FDA decisions using objective public data sources.

Between 2018 and 2024, first attempts to fill brand-name prescription drugs have been denied more often by insurers.

Correct inhaler use among people with COPD can be affected by cognitive function, manual dexterity, and breathing ability.

GLP-1 RA use more than doubled between 2017 and 2022, indicating significant increases among people with and without diabetes.

A recent review found that most drugs for the management of obesity do not improve heart health or quality of life.

Elevated genetic risk for pulse pressure is linked to a higher likelihood of dementia-related mortality among older adults.

The Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP).

The FDA accepts Dyne’s BLA with Priority Review for zeleciment rostudirsen in exon 51 skipping DMD, setting a PDUFA target action date of January 21, 2027.

There is an association between higher p-tau217 levels and increased risk for adverse cognitive outcomes among older adults.

Blood-based biomarkers can help improve accuracy when diagnosing Alzheimer disease and related cognitive impairment or dementia.